Owens & Minor reports Q4 GAAP net loss $296M, adjusted EPS $0.55; exploring sale of P&HS segment

ACCENDRA HEALTH INC/VA/

2024-FY EPS reported -$4.73 revenue$10,700,883,000

Q4 GAAP net loss $296M ($3.84 loss per share); adjusted net income $43M ($0.55 EPS).
Total revenue $2,696M in Q4, $10,701M for FY2024; adjusted EBITDA $138M Q4, $523M FY.
Company actively engaging in discussions for potential sale of Products & Healthcare Services segment.
Board authorized share repurchase program up to $100 million; also reduced debt $244M in 2024.
2025 guidance midpoint expects double-digit adjusted EBITDA and adjusted EPS growth, improving cash flow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.